BioSpace News Archive

Oncocyte Corporation announced that the company will release its fourth quarter and full year 2023 financial results on Friday, April 12, 2024, prior to the U.S. market open.

Rakovina Therapeutics Inc. (TSX-V: RKV), (“Rakovina” or the “Company”) is pleased to announce that members of the Company’s scientific team presented new data on the Company’s novel kt-3000 series at the American Association of Cancer Research (AACR) Annual Meeting at the San Diego Convention Center.

Clinical Laserthermia Systems Americas, Inc. announced it has received its second order from the National Institutes of Health Clinical Center for its TRANBERG™ Thermal Therapy System accessories.

Thermo Fisher Scientific, Inc. is debuting its recently launched innovative products, hosting educational presentations and showcasing live lab demos for customers working in laboratory technology, analysis, biotechnology, and environmental quality during the 2024 Analytica Conference.

Waters Corporation announced the launch of the Alliance iS Bio HPLC System with new capabilities that address the operational and analytical challenges of biopharma quality control laboratories.

Aurinia Pharmaceuticals Inc. announced that it will attend the 2024 Bloom Burton & Co. Healthcare Investor Conference taking place at the Metro Toronto Convention Centre in Toronto from April 16-17, 2024.

Pfizer Announces Positive Top-Line Results from Phase 3 Study of ABRYSVO ® in Adults Aged 18 to 59 at Increased Risk for RSV Disease.

Omega Therapeutics, Inc. today announced the presentation of new preclinical data demonstrating the anti-tumor effect of a MYC-targeting epigenomic controller (MYC-EC) in models of EGFR inhibitor (EGFRi)-resistant non-small cell lung cancer (NSCLC) at the American Association for Cancer Research Annual Meeting 2024, taking place in San Diego, California, April 5 – 10.

Nurix Therapeutics, Inc. announced today an extension of the ongoing research program with Sanofi for STAT6 (signal transducer and activator of transcription 6).

LSL PHARMA GROUP INC, a Canadian integrated pharmaceutical company, announced that it will participate in the Bloom Burton & Co. Healthcare Investor Conference.